<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3326">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01401010</url>
  </required_header>
  <id_info>
    <org_study_id>DORIBAC4006a</org_study_id>
    <nct_id>NCT01401010</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients</brief_title>
  <official_title>Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients With Possible Bacterial Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gary E. Stein, Pharm.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Michigan State University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary: To determine the serum pharmacokinetics (PK) of doripenem in febrile neutropenic
      patients.

      Secondary: Monte Carlo Simulations Tested Against Various Gram-negative Isolates and
      Reported as Probability of Target Attainment (40% Time (fT)&gt; minimum inhibitory
      concentration (MIC))
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Doripenem is a group 2 carbapenem with enhanced in vitro activity against
      Gram-negative bacteria including Pseudomonas aeruginosa. Currently, there is a paucity of
      pharmacokinetic/pharmacodynamic data on doripenem in patients with febrile neutropenia.

      Objectives: To conduct a pharmacokinetic and safety evaluation of two doses of doripenem in
      febrile neutropenic patients and provide probability estimates of attaining effective drug
      exposure against common Gram-negative pathogens.

      Methods: We obtained multiple blood samples from 12 adult patients with febrile neutropenia
      who were receiving either 500 mg or 1000 mg of doripenem IV over 4-hours every 8 hours.
      Following at least 2 doses, serum concentrations were measured in each subject at 1, 4, 6
      and 8 hours after initiation of a dose by a validated HPLC assay. The derived
      pharmacokinetic (PK) parameters from these serum levels were utilized to perform a 5000
      patient Monte Carlo simulation against bacteria with minimal inhibitory concentrations
      (MICs) of 0.008 to 64 mg/L to determine probability estimates of time of free drug
      concentration &gt; MIC (fT&gt;MIC).

      Results: The mean PK parameters in these patients were a volume of distribution (Vd) of
      43.9L, an elimination rate constant (k) of 0.37 hr -1, a total clearance (Cl) of 14.4 L/h,
      and an area under the concentration-time curve (AUC) of 57.6 mg∙h/L. An optimal probability
      of target attainment (40% fT&gt;MIC) of 90% was obtained against bacteria with MICs ≤ 2.0 and ≤
      4.0 mg/L with 500 mg and 1000 mg doses, respectively. Adverse events associated with
      doripenem were not observed in these patients.

      Conclusions: The findings from this analysis of doripenem suggest that higher doses as well
      as prolonged infusions may be necessary to optimally treat selected Gram-negative bacteria
      (eg. Pseudomonas aeruginosa) in patients with febrile neutropenia
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean (SD) Doripenem Pharmacokinetic Volume of Distribution Parameter in Febrile Neutropenic Patients</measure>
    <time_frame>1, 4, 6, 8 hours after at least two doses of drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the serum pharmacokinetic volume of distribution of doripenem in febrile neutropenic patients with pneumonia. We obtained blood at 1, 4, 6, 8 hours after at least two doses of doripenem and measured these levels (mg/L)by HPLC assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean (SD) Doripenem Pharmacokinetic (PK) Elimination Rate Constant Parameter in Febrile Neutropenic Patients</measure>
    <time_frame>1, 4, 6, 8 hours after at least two doses of drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the serum pharmacokinetic elimination rate constant of doripenem in febrile neutropenic patients with pneumonia. We obtained blood at 1, 4, 6, 8 hours after at least two doses of doripenem and measured these levels (mg/L)by HPLC assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean (SD) Doripenem Pharmacokinetic (PK) Half Life Parameter in Febrile Neutropenic Patients</measure>
    <time_frame>1, 4, 6, 8 hours after at least two doses of drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the serum pharmacokinetic half life of doripenem in febrile neutropenic patients with pneumonia. We obtained blood at 1, 4, 6, 8 hours after at least two doses of doripenem and measured these levels (mg/L)by HPLC assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean (SD) Doripenem Pharmacokinetic (PK) Clearance of Drug Parameter in Febrile Neutropenic Patients</measure>
    <time_frame>1, 4, 6, 8 hours after at least two doses of drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the serum pharmacokinetic clearance of drug of doripenem in febrile neutropenic patients with pneumonia. We obtained blood at 1, 4, 6, 8 hours after at least two doses of doripenem and measured these levels (mg/L)by HPLC assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean (SD) Doripenem Pharmacokinetic (PK) Area Under Serum Curve (mg*h/L) Parameter in Febrile Neutropenic Patients</measure>
    <time_frame>1, 4, 6, 8 hours after at least two doses of drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the serum pharmacokinetic area under serum curve of doripenem in febrile neutropenic patients with pneumonia. We obtained blood at 1, 4, 6, 8 hours after at least two doses of doripenem and measured these levels (mg/L)by HPLC assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Monte Carlo Simulations Tested Against Various Gram-negative Isolates and Reported as Probability of Target Attainment (40% Time (fT) &gt; Minimum Inhibitory Concentrations (MIC))</measure>
    <time_frame>1, 4, 6, 8 hours after an infusion of doripenem to determine the PK parameters</time_frame>
    <safety_issue>No</safety_issue>
    <description>Following determination of pharmacokinetic (PK) parameters from patients with febrile neutropenia, Monte Carlo simulations were then conducted to determine time of serum concentrations above the MIC (40% of the time) against Gram-negative isolates.
These Gram-negative isolates had a range of minimum inhibitory concentrations (MIC) to Doripenem.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Febrile Neutropenia</condition>
  <arm_group>
    <arm_group_label>Doripenem 500 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pharmacokinetics/pharmacodynamics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doripenem 1000 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pharmacokinetics/pharmacodynamics</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doripenem</intervention_name>
    <description>500 mg every 8 hours</description>
    <arm_group_label>Doripenem 500 mg</arm_group_label>
    <other_name>Doribac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doripenem</intervention_name>
    <description>1000 mg every 8 hours</description>
    <arm_group_label>Doripenem 1000 mg</arm_group_label>
    <other_name>Doribac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult neutropenic (&lt; 500 cells) patients who are febrile

        Exclusion Criteria:

          -  Patients with Creatinine Clearance &lt; 30 ml/min or allergy to carbapenems will be
             excluded.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Stein, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Michigan State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sparrow Hospital</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 12, 2015</lastchanged_date>
  <firstreceived_date>July 14, 2011</firstreceived_date>
  <firstreceived_results_date>March 6, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Michigan State University</investigator_affiliation>
    <investigator_full_name>Gary E. Stein, Pharm.D.</investigator_full_name>
    <investigator_title>Professor of Medicine and Pharmacology</investigator_title>
  </responsible_party>
  <keyword>neutropenia</keyword>
  <keyword>doripenem</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Febrile Neutropenia</mesh_term>
    <mesh_term>Fever</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were inpatients (Sparrow Hospital) with febrile neutropenia who were treated with doripenem; referral base was infectious disease consultations. The first patient was enrolled 6-15-2010 and the last 8-21-2011.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Doripenem 500 mg</title>
          <description>pharmacokinetics/pharmacodynamics</description>
        </group>
        <group group_id="P2">
          <title>Doripenem 1000 mg</title>
          <description>pharmacokinetics/pharmacodynamics</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Could not interpret assay results</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Doripenem 500 mg</title>
          <description>pharmacokinetics/pharmacodynamics</description>
        </group>
        <group group_id="B2">
          <title>Doripenem 1000 mg</title>
          <description>pharmacokinetics/pharmacodynamics</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="49" spread="17"/>
                <measurement group_id="B2" value="49" spread="18"/>
                <measurement group_id="B3" value="49" spread="17.5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean (SD) Doripenem Pharmacokinetic Volume of Distribution Parameter in Febrile Neutropenic Patients</title>
        <description>To determine the serum pharmacokinetic volume of distribution of doripenem in febrile neutropenic patients with pneumonia. We obtained blood at 1, 4, 6, 8 hours after at least two doses of doripenem and measured these levels (mg/L)by HPLC assay.</description>
        <time_frame>1, 4, 6, 8 hours after at least two doses of drug</time_frame>
        <safety_issue>No</safety_issue>
        <population>Each subject received drug and had serum samples drawn at 1, 4, 6, 8 hours after dosing.</population>
        <group_list>
          <group group_id="O1">
            <title>Doripenem 500 mg</title>
            <description>Mean (SD) Doripenem Pharmacokinetic (PK) Parameters in Febrile Neutropenic Patients Who Received 500mg Dosing</description>
          </group>
          <group group_id="O2">
            <title>Doripenem 1000 mg</title>
            <description>Mean (SD) Doripenem Pharmacokinetic (PK) Parameters in Febrile Neutropenic Patients Who Received 1000 mg Dosing</description>
          </group>
          <group group_id="O3">
            <title>Combined Results for Both 500 and 1000 mg</title>
            <description>Mean (SD) Doripenem Pharmacokinetic (PK) Parameters in Febrile Neutropenic Patients Combined Results</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean (SD) Doripenem Pharmacokinetic Volume of Distribution Parameter in Febrile Neutropenic Patients</title>
            <description>To determine the serum pharmacokinetic volume of distribution of doripenem in febrile neutropenic patients with pneumonia. We obtained blood at 1, 4, 6, 8 hours after at least two doses of doripenem and measured these levels (mg/L)by HPLC assay.</description>
            <units>Liters</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="36.7" spread="15.9"/>
                  <measurement group_id="O2" value="49.9" spread="18.1"/>
                  <measurement group_id="O3" value="43.9" spread="17.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Monte Carlo Simulations Tested Against Various Gram-negative Isolates and Reported as Probability of Target Attainment (40% Time (fT) &gt; Minimum Inhibitory Concentrations (MIC))</title>
        <description>Following determination of pharmacokinetic (PK) parameters from patients with febrile neutropenia, Monte Carlo simulations were then conducted to determine time of serum concentrations above the MIC (40% of the time) against Gram-negative isolates.
These Gram-negative isolates had a range of minimum inhibitory concentrations (MIC) to Doripenem.</description>
        <time_frame>1, 4, 6, 8 hours after an infusion of doripenem to determine the PK parameters</time_frame>
        <safety_issue>No</safety_issue>
        <population>Each subject received drug and had serum samples drawn at 1, 4, 6, 8 hours after dosing.</population>
        <group_list>
          <group group_id="O1">
            <title>500 mg Doripenem 1 Hour Infusion</title>
            <description>Probability of target attainment (40%fT&gt;MIC) against Gram-negative pathogens using Monte Carlo simulations</description>
          </group>
          <group group_id="O2">
            <title>500 mg Doripenem 4 Hour Infusion</title>
            <description>Probability of target attainment (40%fT&gt;MIC) against Gram-negative pathogens using Monte Carlo simulations</description>
          </group>
          <group group_id="O3">
            <title>1000 mg Doripenem 1 Hour Infusion</title>
            <description>Probability of target attainment (40%fT&gt;MIC) against Gram-negative pathogens using Monte Carlo simulations</description>
          </group>
          <group group_id="O4">
            <title>1000 mg Doripenem 4 Hour Infusion</title>
            <description>Probability of target attainment (40%fT&gt;MIC) against Gram-negative pathogens using Monte Carlo simulations</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Monte Carlo Simulations Tested Against Various Gram-negative Isolates and Reported as Probability of Target Attainment (40% Time (fT) &gt; Minimum Inhibitory Concentrations (MIC))</title>
            <description>Following determination of pharmacokinetic (PK) parameters from patients with febrile neutropenia, Monte Carlo simulations were then conducted to determine time of serum concentrations above the MIC (40% of the time) against Gram-negative isolates.
These Gram-negative isolates had a range of minimum inhibitory concentrations (MIC) to Doripenem.</description>
            <units>probability of target attainment</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>E. coli MIC: 0.06 mg/L</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>K. pneumoniae MIC: 0.12 mg/L</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.99"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P. mirabilis MIC: 0.50 mg/L</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.99"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0.99"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E. cloacae MIC: 0.25 mg/L</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.99"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0.99"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>S. marcescens MIC: 0.25 mg/L</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.99"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0.99"/>
                  <measurement group_id="O4" value="0.99"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>P. aeruginosa MIC: 4 mg/L</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.55"/>
                  <measurement group_id="O2" value="0.63"/>
                  <measurement group_id="O3" value="0.87"/>
                  <measurement group_id="O4" value="0.94"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean (SD) Doripenem Pharmacokinetic (PK) Elimination Rate Constant Parameter in Febrile Neutropenic Patients</title>
        <description>To determine the serum pharmacokinetic elimination rate constant of doripenem in febrile neutropenic patients with pneumonia. We obtained blood at 1, 4, 6, 8 hours after at least two doses of doripenem and measured these levels (mg/L)by HPLC assay.</description>
        <time_frame>1, 4, 6, 8 hours after at least two doses of drug</time_frame>
        <safety_issue>No</safety_issue>
        <population>Each subject received drug and had serum samples drawn at 1, 4, 6, 8 hours after dosing.</population>
        <group_list>
          <group group_id="O1">
            <title>Doripenem 500 mg</title>
            <description>Mean (SD) Doripenem Pharmacokinetic (PK) Parameters in Febrile Neutropenic Patients Who Received 500mg Dosing</description>
          </group>
          <group group_id="O2">
            <title>Doripenem 1000 mg</title>
            <description>Mean (SD) Doripenem Pharmacokinetic (PK) Parameters in Febrile Neutropenic Patients Who Received 1000 mg Dosing</description>
          </group>
          <group group_id="O3">
            <title>Combined Results for Both 500 and 1000 mg</title>
            <description>Mean (SD) Doripenem Pharmacokinetic (PK) Parameters in Febrile Neutropenic Patients Combined Results</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean (SD) Doripenem Pharmacokinetic (PK) Elimination Rate Constant Parameter in Febrile Neutropenic Patients</title>
            <description>To determine the serum pharmacokinetic elimination rate constant of doripenem in febrile neutropenic patients with pneumonia. We obtained blood at 1, 4, 6, 8 hours after at least two doses of doripenem and measured these levels (mg/L)by HPLC assay.</description>
            <units>hour^-1</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.36" spread="0.14"/>
                  <measurement group_id="O2" value="0.38" spread="0.20"/>
                  <measurement group_id="O3" value="0.37" spread="0.17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean (SD) Doripenem Pharmacokinetic (PK) Half Life Parameter in Febrile Neutropenic Patients</title>
        <description>To determine the serum pharmacokinetic half life of doripenem in febrile neutropenic patients with pneumonia. We obtained blood at 1, 4, 6, 8 hours after at least two doses of doripenem and measured these levels (mg/L)by HPLC assay.</description>
        <time_frame>1, 4, 6, 8 hours after at least two doses of drug</time_frame>
        <safety_issue>No</safety_issue>
        <population>Each subject received drug and had serum samples drawn at 1, 4, 6, 8 hours after dosing.</population>
        <group_list>
          <group group_id="O1">
            <title>Doripenem 500 mg</title>
            <description>Mean (SD) Doripenem Pharmacokinetic (PK) Parameters in Febrile Neutropenic Patients Who Received 500mg Dosing</description>
          </group>
          <group group_id="O2">
            <title>Doripenem 1000 mg</title>
            <description>Mean (SD) Doripenem Pharmacokinetic (PK) Parameters in Febrile Neutropenic Patients Who Received 1000 mg Dosing</description>
          </group>
          <group group_id="O3">
            <title>Combined Results for Both 500 and 1000 mg</title>
            <description>Mean (SD) Doripenem Pharmacokinetic (PK) Parameters in Febrile Neutropenic Patients Combined Results</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean (SD) Doripenem Pharmacokinetic (PK) Half Life Parameter in Febrile Neutropenic Patients</title>
            <description>To determine the serum pharmacokinetic half life of doripenem in febrile neutropenic patients with pneumonia. We obtained blood at 1, 4, 6, 8 hours after at least two doses of doripenem and measured these levels (mg/L)by HPLC assay.</description>
            <units>hours</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.2" spread="0.84"/>
                  <measurement group_id="O2" value="2.4" spread="1.3"/>
                  <measurement group_id="O3" value="2.3" spread="1.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean (SD) Doripenem Pharmacokinetic (PK) Clearance of Drug Parameter in Febrile Neutropenic Patients</title>
        <description>To determine the serum pharmacokinetic clearance of drug of doripenem in febrile neutropenic patients with pneumonia. We obtained blood at 1, 4, 6, 8 hours after at least two doses of doripenem and measured these levels (mg/L)by HPLC assay.</description>
        <time_frame>1, 4, 6, 8 hours after at least two doses of drug</time_frame>
        <safety_issue>No</safety_issue>
        <population>Each subject received drug and had serum samples drawn at 1, 4, 6, 8 hours after dosing.</population>
        <group_list>
          <group group_id="O1">
            <title>Doripenem 500 mg</title>
            <description>Mean (SD) Doripenem Pharmacokinetic (PK) Parameters in Febrile Neutropenic Patients Who Received 500mg Dosing</description>
          </group>
          <group group_id="O2">
            <title>Doripenem 1000 mg</title>
            <description>Mean (SD) Doripenem Pharmacokinetic (PK) Parameters in Febrile Neutropenic Patients Who Received 1000 mg Dosing</description>
          </group>
          <group group_id="O3">
            <title>Combined Results for Both 500 and 1000 mg</title>
            <description>Mean (SD) Doripenem Pharmacokinetic (PK) Parameters in Febrile Neutropenic Patients Combined Results</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean (SD) Doripenem Pharmacokinetic (PK) Clearance of Drug Parameter in Febrile Neutropenic Patients</title>
            <description>To determine the serum pharmacokinetic clearance of drug of doripenem in febrile neutropenic patients with pneumonia. We obtained blood at 1, 4, 6, 8 hours after at least two doses of doripenem and measured these levels (mg/L)by HPLC assay.</description>
            <units>Liters/hour</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11.9" spread="2.2"/>
                  <measurement group_id="O2" value="16.6" spread="6.8"/>
                  <measurement group_id="O3" value="14.4" spread="5.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean (SD) Doripenem Pharmacokinetic (PK) Area Under Serum Curve (mg*h/L) Parameter in Febrile Neutropenic Patients</title>
        <description>To determine the serum pharmacokinetic area under serum curve of doripenem in febrile neutropenic patients with pneumonia. We obtained blood at 1, 4, 6, 8 hours after at least two doses of doripenem and measured these levels (mg/L)by HPLC assay.</description>
        <time_frame>1, 4, 6, 8 hours after at least two doses of drug</time_frame>
        <safety_issue>No</safety_issue>
        <population>Each subject received drug and had serum samples drawn at 1, 4, 6, 8 hours after dosing.</population>
        <group_list>
          <group group_id="O1">
            <title>Doripenem 500 mg</title>
            <description>Mean (SD) Doripenem Pharmacokinetic (PK) Parameters in Febrile Neutropenic Patients Who Received 500mg Dosing</description>
          </group>
          <group group_id="O2">
            <title>Doripenem 1000 mg</title>
            <description>Mean (SD) Doripenem Pharmacokinetic (PK) Parameters in Febrile Neutropenic Patients Who Received 1000 mg Dosing</description>
          </group>
          <group group_id="O3">
            <title>Combined Results for Both 500 and 1000 mg</title>
            <description>Mean (SD) Doripenem Pharmacokinetic (PK) Parameters in Febrile Neutropenic Patients Combined Results</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean (SD) Doripenem Pharmacokinetic (PK) Area Under Serum Curve (mg*h/L) Parameter in Febrile Neutropenic Patients</title>
            <description>To determine the serum pharmacokinetic area under serum curve of doripenem in febrile neutropenic patients with pneumonia. We obtained blood at 1, 4, 6, 8 hours after at least two doses of doripenem and measured these levels (mg/L)by HPLC assay.</description>
            <units>milligrams * hour/liters</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="47.1" spread="13.2"/>
                  <measurement group_id="O2" value="66.4" spread="33.1"/>
                  <measurement group_id="O3" value="57.6" spread="26.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Doripenem 500 mg</title>
          <description>pharmacokinetics/pharmacodynamics</description>
        </group>
        <group group_id="E2">
          <title>Doripenem 1000 mg</title>
          <description>pharmacokinetics/pharmacodynamics</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gary E Stein</name_or_title>
      <organization>Michigan State University</organization>
      <phone>517-353-5126</phone>
      <email>Gary.Stein@hc.msu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
